These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

52 related items for PubMed ID: 9595829

  • 21. Comparison of bovine in vivo bioavailability of two sulfamethazine oral boluses exhibiting different in vitro dissolution profiles.
    Martinez MN, Kawalek JC, Howard KD, Ward JL, Marroum P, Marnane W, Bensley D, Pelsor FR, Hoag S, Tatavarti AS, Xie L, Fahmy R.
    J Vet Pharmacol Ther; 2006 Dec; 29(6):459-67. PubMed ID: 17083449
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form.
    Souliman S, Blanquet S, Beyssac E, Cardot JM.
    Eur J Pharm Sci; 2006 Jan; 27(1):72-9. PubMed ID: 16169713
    [Abstract] [Full Text] [Related]

  • 24. A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant.
    Iyer SS, Barr WH, Karnes HT.
    Int J Pharm; 2007 Aug 01; 340(1-2):119-25. PubMed ID: 17482777
    [Abstract] [Full Text] [Related]

  • 25. Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.
    Costantini LC, Kleppner SR, McDonough J, Azar MR, Patel R.
    Int J Pharm; 2004 Sep 28; 283(1-2):35-44. PubMed ID: 15363499
    [Abstract] [Full Text] [Related]

  • 26. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone.
    Pillai O, Hamad MO, Crooks PA, Stinchcomb AL.
    Pharm Res; 2004 Jul 28; 21(7):1146-52. PubMed ID: 15290853
    [Abstract] [Full Text] [Related]

  • 27. An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6beta-naltrexol in dog and human plasma.
    Clavijo C, Bendrick-Peart J, Zhang YL, Johnson G, Gasparic A, Christians U.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Oct 15; 874(1-2):33-41. PubMed ID: 18805072
    [Abstract] [Full Text] [Related]

  • 28. Acute opioid pretreatment potentiates naltrexone-induced drinking suppression in water-deprived rats.
    White DA, Holtzman SG.
    J Pharmacol Exp Ther; 2001 Jul 15; 298(1):156-64. PubMed ID: 11408537
    [Abstract] [Full Text] [Related]

  • 29. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro.
    Banks SL, Pinninti RR, Gill HS, Crooks PA, Prausnitz MR, Stinchcomb AL.
    Pharm Res; 2008 Jul 15; 25(7):1677-85. PubMed ID: 18449628
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases.
    Brewer C.
    Addict Biol; 2002 Jul 15; 7(3):321-3. PubMed ID: 12126492
    [Abstract] [Full Text] [Related]

  • 34. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation.
    Fahmy RH, Kassem MA.
    Eur J Pharm Biopharm; 2008 Aug 15; 69(3):993-1003. PubMed ID: 18396390
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.